ACTRN12618000350224尚未招募1 期
A Phase 1, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of oral ETX0282 Administered in Healthy Subjects
INC Research/ Inventiv Health0 个研究点目标入组 116 人开始时间: 2018年3月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy SubjectsACTRN12616001040459Clinical Network Services128
已完成
不适用
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-440 Alone and in Combination with VX-661/Ivacaftor, and Bioavailability and Food Effect of VX-440 in Healthy Adult Subjects10038686cystic fibrosisNL-OMON43882Vertex Pharmaceuticals120
招募中
1 期
A First-in-Human Study of SGB-9768 in Healthy VolunteersComplement-mediated DiseasesInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12624000054516Sanegene Bio New Zealand Ltd36
进行中（未招募）
1 期
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Axatilimab When Administered by Intravenous Infusion to Healthy Japanese ParticipantsJPRN-jRCT2071220109eda Eiji20
已完成
1 期
A study to investigate ARG-007 in Healthy VolunteersStroke - IschaemicStrokeACTRN12622001209785Argenica Therapeutics Ltd.32